5,500
Participants
Start Date
December 26, 2023
Primary Completion Date
December 31, 2029
Study Completion Date
December 31, 2034
GALAD
GALAD is a 3 biomarker panel incorporating AFP, AFP-L3% and DCP (all FDA approved), with patient age and sex.
Liver Ultrasound with or without AFP
This intervention consists of current standard of care ultrasound based surveillance with or without alpha-fetoprotein measurement.
RECRUITING
The Feinstein Institutes, Northwell Health, Inc., Manhasset
RECRUITING
University of Pennsylvania, Philadelphia
NOT_YET_RECRUITING
Virginia Commonwealth University, Richmond
RECRUITING
University of North Carolina, Chapel Hill
RECRUITING
Indiana University, Indianapolis
RECRUITING
University of Michigan, Ann Arbor
RECRUITING
Henry Ford Health System, Detroit
RECRUITING
Hennepin Healthcare, Minneapolis
RECRUITING
University of Minnesota, Minneapolis
RECRUITING
Northwestern University, Chicago
RECRUITING
UT Southwestern Medical Center and Parkland Hospital, Dallas
RECRUITING
Baylor College of Medicine, Houston
RECRUITING
University of Southern California, Los Angeles
RECRUITING
Stanford University, Redwood City
RECRUITING
University of California, San Francisco, San Francisco
RECRUITING
Kaiser Permanente, Roseville
RECRUITING
Massachusetts General Hospital, Boston
National Cancer Institute (NCI)
NIH
University of Pennsylvania
OTHER
University of Michigan
OTHER
Dana-Farber Cancer Institute
OTHER
Baylor College of Medicine
OTHER
Fred Hutchinson Cancer Center
OTHER
University of Texas Southwestern Medical Center
OTHER